Company Scancell Holdings plc

Equities

SCLP

GB00B63D3314

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:25 2024-04-26 am EDT			5-day change	1st Jan Change
9.6 ^GBX	0.00%		0.00%	-8.57%

Mar. 26	Scancell doses first patient in melanoma-focused trials	AN
Mar. 14	Scancell Holdings plc Appoints Sath Nirmalananthan to the Board	CI

Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its products pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. SCIB1 is the lead product from its ImmunoBody immunotherapy platform, which identifies, attacks and destroys tumors. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.

Number of employees: 51

GBP in Million	2022	Weight	2023	Weight	Delta
Novel Vaccine and Antibody Medicines 100.0 %	0	nan %	5	100.0 %	-

GBP in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	0	nan %	5	100.0 %	-

Managers	Title	Age	Since
Linda Durrant CEO	Chief Executive Officer	67	96-12-31
Sath Nirmalananthan DFI	Director of Finance/CFO	38	23-08-28
Fayaz Master CTO	Chief Tech/Sci/R&D Officer	-	-
Robert Matthew Miller CTO	Chief Tech/Sci/R&D Officer	-	20-11-16
Mandeep Sehmi PRN	Corporate Officer/Principal	-	23-09-06
Keith Green SEC	Corporate Secretary	-	16-08-31
Samantha Paston PRN	Corporate Officer/Principal	-	19-01-14

Members of the board	Title	Age	Since
Jean-Michel Cossery CHM	Chairman	65	23-01-31
Ursula Ney BRD	Director/Board Member	72	19-10-22
Linda Durrant CEO	Chief Executive Officer	67	96-12-31
Martin Diggle BRD	Director/Board Member	62	19-06-17
Susan Clement Davies BRD	Director/Board Member	62	20-09-23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	927,979,977	849,259,697 ( 91.52 %)	0	91.52 %

Name	Equities	%	Valuation
Redmile Group LLC 28.95 %	268,616,936	28.95 %	35 M p
Vulpes Investment Management Pte Ltd. 12.92 %	119,910,847	12.92 %	16 M p
Hygea VCT Plc (Private Equity) 1.180 %	10,948,807	1.180 %	1 M p
ISPartners Investment Solutions AG 0.7838 %	7,272,012	0.7838 %	941 580 p
Maven Capital Partners UK LLP 0.4367 %	4,051,761	0.4367 %	524 622 p
Calculus Capital Ltd. 0.2754 %	2,554,777	0.2754 %	330 793 p
Linda Durrant 0.2231 %	2,069,962	0.2231 %	268 019 p
Jean-Michel Cossery 0.0490 %	454,720	0.0490 %	58 877 p
Sally Adams 0.008484 %	78,714	0.008484 %	10 192 p
Edale Capital LLP 0.004433 %	41,127	0.004433 %	5 325 p

Scancell Holdings Plc

Bellhouse Building, Unit 202 Sanders Road

OX4 4GD, Oxford

+44 18 6558 2066

http://www.scancell.co.uk

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.096 GBP

Average target price

0.2473 GBP

Spread / Average Target

+157.64%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
SCANCELL HOLDINGS PLC	-8.57%	98.03M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research